Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of BK1310 vs ActHIB + Tetrabik in healthy infants
jRCT2080224611Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of MT-2355 in Haemophilus influenzae type b disease (Hib), pertussis, diphtheria and 2 more (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Antibody retention rates after primary immunization. Started Mar 2019; status: completed.
02
Drugs
MT-2355
03
Conditions
Haemophilus influenzae type b disease (Hib)pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCT2080224611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224611.